logo

Clinical Trial Calendar

Announced Date
Company Name
Ticker
Event
Indication
Period
Outcome
Details
12/03/2014
CytRx Corp.
Preliminary results from phase II trial of Aldoxorubicin
Kaposi's Sarcoma
1H 2015
12/03/2014
CytRx Corp.
Preliminary results from phase II trial of Aldoxorubicin
Glioblastoma multiforme
1H 2015
01/06/2015
Can-Fite BioPharma Ltd.
Data from Phase II study of CF101
Glaucoma.
1H 2015
12/22/2014
Apricus Biosciences, Inc.
Results from phase 2a trial of RayVa
Raynaud's phenomenon, a circulatory disorder affecting the hands and feet.
Q2 2015
01/12/2015
Vital Therapies, Inc
Topline data from Phase 3 study of VTI-208
Alcohol induced liver decompensation
Q2 2015
01/07/2015
Genocea Biosciences, Inc.
Topline data from Phase 2 trial of GEN-003
Genital herpes
Late Q2 2015
11/10/2014
GTX Inc.
Topline data from Phase 2 study of GTx-758
Metastatic and non-metastatic castration resistant prostate cancer
Q2 2015
03/04/2015
Eleven Biotherapeutics, Inc.
Top-line results from phase 3 study of EBI-005
Dry eye disease
Q2 2015
03/11/2015
Conatus Pharmaceuticals Inc
Initial baseline data from phase 2 study of Emricasan
Post Orthotopic Liver Transplant for Chronic HCV patients
Q2 2015
03/18/2015
Otonomy Inc.
Results from Phase 2b trial of OTO-104
Meniere's disease
Q2 2015
03/25/2015
Ardelyx, Inc
Phase 2a Data for Tenapanor
Chronic kidney disease
Q2 2015
12/11/2014
Vical Inc.
Efficacy data from phase 1/2 trial of Vaxfectin(R)-formulated therapeutic vaccine
Herpes simplex virus type 2 (HSV-2)
Mid 2015
01/06/2015
Trevena, Inc.
Data from Phase 2b Study of TRV130
Acute Postoperative Pain
Mid 2015
11/11/2014
Fate Therapeutics, Inc
Full data on primary efficacy endpoint from phase II study of PROHEMA
Hematologic malignancies
Mid 2015
12/15/2014
Celldex Therapeutics Inc.
First interim analysis of phase III 3 Study of Rindopepimut
Frontline Glioblastoma
Mid 2015